Trials / Unknown
UnknownNCT04069325
Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy
Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy：a Randomized Controlled Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the efficacy and safety of simiaowan in prevention of acute flares in chronic gout patients initiating febuxostat therapy.
Detailed description
The study is a multicenter, randomized, double-blind, placebo-controlled, 12-week trial. To determine whether oral simiaowan at standard clinical doses (6g twice daily), compared to placebo, can reduce the incidence of acute gout flares and decrease the serum uric acid level.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | simiaowan | pills, 6g twice daily (BID), oral, 12 weeks |
| DRUG | placebo | pills, 6g twice daily (BID), oral, 12 weeks |
| DRUG | febuxostat | tablets, 40 mg once daily (QD), oral, 12 weeks |
Timeline
- Start date
- 2019-09-01
- Primary completion
- 2020-07-28
- Completion
- 2020-07-28
- First posted
- 2019-08-28
- Last updated
- 2019-08-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04069325. Inclusion in this directory is not an endorsement.